Comparison of reporting between sources in METRIC
| Outcomes | Population | Flaherty et al16 | ClinicalTrials.gov | Clinical study report |
|---|---|---|---|---|
| PFS (median) | BRAF V600E +ve participants without a history of brain metastases | ✕ (HR available) | ✓ | ✓ |
| All participants | ✓ | ✓ | ✓ | |
| BRAF V600E +ve participants without a history of brain metastases and without prior chemotherapy | ✕ (HR available) | ✓ (HR not available) | ✓ | |
| BRAF V600E +ve participants without a history of brain metastases and with prior chemotherapy | ✕ (HR available) | ✓ (HR not available) | ✓ | |
| OS (median) | All participants | ✓ | ✓ | ✓ |
| BRAF V600E +ve participants without a history of brain metastases | ✕ | ✓ | ✓ | |
| ORR | BRAF V600E +ve participants without a history of brain metastases | ✕ | ✓ | ✓ |
| All participants | ✓ | ✓ | ✓ | |
| CR/PR | BRAF V600E +ve participants | ✕ | ✓ | ✓ |
| BRAF V600K +ve participants | ✕ | ✓ | ✓ | |
| DOR (median) | Number of participants with OR following crossover to trametinib | ✕ | ✓ | ✓ |
| BRAF V600 +ve participants without a prior history of brain metastases | ✕ | ✓ | ✓ | |
| All participants | ✓ | ✓ | ✓ | |
| All responders following crossover to trametinib | ✕ | ✓ | ✓ | |
| PFS following crossover to trametinib | ✕ | ✓ | ✓ |
CR, complete response; DOR, duration of response; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PR, partial response.